Palleon Pharmaceuticals attracts $47.6 mln Series A
Waltham, Massachusetts-based Palleon Pharmaceuticals, a developer of glycoimmune checkpoint inhibitors that treat cancer, has closed $47.6 million in Series A financing. The investors were SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures and AbbVie Ventures.
5 October 2017•1 min read
